Replies to post #24757 on Biotech Values

[DewDiligence]

Tysabri vs Copaxone Revisited

A year ago, this board ran a survey on which of these drugs will have larger sales in 2007-2009. Tysabri outpolled Copaxone by almost 2:1:

http://www.investorshub.com/boards/board_survey_results.asp?board_id=1418&Survey_Num=47

It looks like the majority of survey voters got it wrong. 4Q06 worldwide sales of Tysabri (reported today by BIIB) were $30M. 4Q06 worldwide sales of Copaxone were $378M.

I think it’s not unreasonable to think that Copaxone will continue to outsell Tysabri by about 10:1.

[masterlongevity]

that survey is very much out o dat and i don't think people would have the same answers in today's environment